文献速递淋巴瘤浆细胞疾病造血干细胞移植与细胞治疗

接受CAR-T细胞治疗患者的克隆性造血

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在154例接受CAR-T细胞治疗的非霍奇金淋巴瘤或多发性骨髓瘤患者中评估克隆性造血(CHIP)对临床结局的影响。结果显示CHIP存在于48%的患者中,且仅在60岁以下患者中与完全缓解率升高和细胞因子释放综合征严重程度增加相关。无论年龄如何,CHIP与无进展生存期或总生存期差异无关。

要点

  • CAR-T治疗患者中CHIP发生率为48%。
  • 60岁以下患者中,CHIP与完全缓解率升高及CRS严重程度增加相关。
  • CHIP与无进展生存期或总生存期差异无关,不应作为排除CAR-T治疗的理由。

核心结论

  • CHIP可影响CAR-T细胞生物学和临床结局,但与自体移植不同,CHIP与更差生存无关,不应成为排除患者接受CAR-T治疗的理由。

研究设计与样本

  • 回顾性队列研究,纳入154例接受CAR-T细胞治疗的非霍奇金淋巴瘤或多发性骨髓瘤患者。

主要发现

  • CHIP存在于48%的患者中。
  • 仅在60岁以下患者中,CHIP与完全缓解率升高和细胞因子释放综合征严重程度增加相关。
  • 无论年龄如何,CHIP与无进展生存期或总生存期差异无关。

临床怎么用

  • CHIP不应作为排除患者接受CAR-T细胞治疗的理由。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cells have emerged as an efficacious modality in patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). Clonal hematopoiesis of indeterminate potential (CHIP), a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is more common in patients exposed to cytotoxic therapies, has been shown to influence inflammatory immune programs, and is associated with an adverse prognosis in patients with NHL and MM receiving autologous transplantation. We therefore hypothesized that CHIP could influence clinical outcomes in patients receiving CAR T-cell therapy. In a cohort of 154 patients with NHL or MM receiving CAR T-cells, we found that CHIP was present in 48% of patients and associated with increased rates of complete response and cytokine release syndrome severity, but only in patients younger than age 60 years. Despite these differences, CHIP was not associated with a difference in progression-free or overall survival, regardless of age. Our data suggest that CHIP can influence CAR T-cell biology and clinical outcomes, but, in contrast to autologous transplantation, CHIP was not associated with worse survival and should not be a reason to exclude individuals from receiving this potentially life-prolonging treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Miller PG, Sperling AS, Brea EJ, et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021. PMID: 34342642. doi:10.1182/bloodadvances.2021004554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。